Plain-English translation of NCT07616453 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a clinical trial testing a new approach to treating early-stage breast cancer in women whose tumors are hormone-positive but not HER2-positive. The study uses a medication called combined with hormone therapy (), and doctors will check how well the cancer is responding partway through treatment. If the cancer is responding well, you continue the same treatment. If it's not responding as expected, your doctor will switch you to a different treatment plan before surgery.
Many women with this type of breast cancer respond differently to the same treatment, and some tumors don't respond well to standard hormone therapy alone. This trial aims to find a smarter way to treat these cancers by tailoring the approach based on early signs of whether the medication is working, so each patient gets the treatment most likely to help her.
You likely qualify if…
You likely don't qualify if…
You will take and hormone therapy pills as prescribed before surgery. After a set period of treatment, doctors will assess how well your cancer is responding using imaging and blood tests. Depending on those results, you may continue the same treatment or switch to a different regimen. You'll have regular doctor visits, blood work, heart monitoring, and scans throughout the study to track how you're doing and watch for any side effects. The entire study period covers your neoadjuvant (pre-surgery) treatment phase before you undergo surgery.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China